These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 795108)

  • 21. Relationship of tumor-specific transplantation antigens to the histocompatibility complex: dissociation of in vitro alloantigen expression and in vivo alloimmunity from tumor-specific transplantation antigen strength.
    Chauvenet PH; Smith RT
    Int J Cancer; 1978 Jul; 22(1):79-90. PubMed ID: 79560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative immunogenicity and enhanceability of individual H-2K and H-2D specificities of the murine histocompatibility-2 complex.
    McKenzie IF; Snell GD
    J Exp Med; 1973 Jul; 138(1):259-77. PubMed ID: 4123828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H-2 mutation affecting immune response to Thy-1.1 antigen.
    Zaleski M; Klein J
    J Exp Med; 1977 Jun; 145(6):1602-6. PubMed ID: 140918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serological distinction of mutants B6.CH(zl) and B6.M505 from strain C57BL-6.
    Klein J; Hauptfeld M; Hauptfeld V
    J Exp Med; 1974 Oct; 140(4):1127-32. PubMed ID: 4139224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T lymphocytes specific for I region determinants do not require interactions with H-2K or D gene products.
    Billings P; Burakoff S; Dorf ME; Benacerraf B
    J Exp Med; 1977 May; 145(5):1387-92. PubMed ID: 67179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A method for detection of Ia antigens in the absence of appropriate H-2 recombinants.
    Hauptfeld M; Hauptfeld V; Klein J
    J Immunol; 1975 Aug; 115(2):351-5. PubMed ID: 1080169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression.
    Ishikawa H; Saito K; Kubota E
    J Immunol; 1989 Mar; 142(5):1495-9. PubMed ID: 2918225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serological cross-reaction between H-2D and H-2K region antigens.
    David CS; Shreffler DC; Murphy DB; Klein J
    Transplant Proc; 1973 Mar; 5(1):287-93. PubMed ID: 4572101
    [No Abstract]   [Full Text] [Related]  

  • 29. Cytotoxic T-cell response to Ectromelia virus-infected cells. Different H-2 requirements for triggering precursor T-cell induction or lysis by effector T cells defined by the BALB/c-H-2db mutation.
    Blanden RV; McKenzie IF; Kees U; Melvold RW; Kohn HI
    J Exp Med; 1977 Sep; 146(3):869-80. PubMed ID: 70498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histocompatibility-2 system in wild mice. II. H-2 haplotypes of t-bearing mice.
    Hammerberg C; Klein J; Artzt K; Bennett D
    Transplantation; 1976 Mar; 21(3):199-212. PubMed ID: 941210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular heterogeneity of D-end products detected by anti-H-2.28 sera. II. B10.D2(M504) (H-2dm1) mutant fails to express one of the two H-2.4-, 28 + Dd region molecules.
    Iványi D; Démant P
    Immunogenetics; 1982; 15(5):467-76. PubMed ID: 6980826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural differences between the mouse H-2D products of the mutant B10.D2.M504 (H-2da) and the parental nonmutant strain B10.D2 (H-2d).
    Brown JL; Nairen R; Natherson SG
    J Immunol; 1978 Mar; 120(3):726-33. PubMed ID: 632584
    [No Abstract]   [Full Text] [Related]  

  • 33. Independence of H-2K and H-2D antigenic determinants on the surface of mouse lymphocytes.
    Neauport-Sautes C; Lilly F; Silvestre D; Kourilsky FM
    J Exp Med; 1973 Feb; 137(2):511-26. PubMed ID: 4119593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for mutation in an I-A gene.
    Hansen TH; Melvold RW; Arn JS; Sachs DH
    Nature; 1980 May; 285(5763):340-1. PubMed ID: 7374785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ia versus K/D antigens in immunological enhancement of tumour allografts. II. Studies with alloimmune sera prepared in recombinant strains.
    Duc HT; Kinsky RG; Voisin GA
    Ann Immunol (Paris); 1979; 130C(3):461-74. PubMed ID: 475347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.
    Germain RN; Dorf ME; Benacerraf B
    J Exp Med; 1975 Oct; 142(4):1023-8. PubMed ID: 809532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on recombination within the mouse H-2 gene complex. III. Further serological analyses of the H-2t haplotypes.
    David CS; Hansen TH; Shreffler C
    Tissue Antigens; 1975 Nov; 6(5):353-65. PubMed ID: 1216250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recombinant haplotype H-2 in mice of the congenic resistant strain B10.D1(R108)/Y].
    Blandova ZK; Capková J; Pospelov LE; Nikonenko BV; Apt AS
    Genetika; 1984 Sep; 20(9):1484-8. PubMed ID: 6389262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary antibody response against K and D regions of the H-2a and H-2d haplotypes.
    Malavé I; Fuji H
    Transplantation; 1975 Dec; 20(6):492-8. PubMed ID: 54966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. H-2 antigenicity of Leydig cells.
    Vojtísková M; Pokorná Z; Kristofová H; Polácková M; Rícarová-Vorácová B
    Folia Biol (Praha); 1981; 27(3):163-70. PubMed ID: 7021209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.